Clinical Pharmacology & Therapeutics · 2018 · 68 citations · 20 references
MedicinePharmacokineticsPharmacologyClinical PharmacologyMolecular PharmacologyPharmacodynamicsDose SelectionTyrosine Kinase InhibitorsBruton Tyrosine KinaseBruton's Tyrosine Kinase InhibitorsBtk InhibitorsProtein Kinase InhibitorsReversible Tyrosine Kinase InhibitorsSmall Molecule Tyrosine Kinase InhibitorsTyrosine Kinase InhibitionTyrosine Kinase Inhibitor Pharmacokinetics
GDC-0853 is a small molecule inhibitor of Bruton's tyrosine kinase (BTK) that is highly selective and noncovalent, leading to reversible binding. In double-blind, randomized, and placebo-controlled phase I healthy volunteer studies, GDC-0853 was well tolerated, with no dose-limiting adverse events (AEs) or serious AEs. The maximum tolerated dose was not reached during dose escalation (≤600 mg, single ascending dose (SAD) study; ≤250 mg twice daily (b.i.d.) and ≤500 mg once daily, 14-day multiple ascending dose (MAD) study). Plasma concentrations peaked 1-3 hours after oral administration and declined thereafter, with a steady-state half-life ranging from 4.2-9.9 hours. Independent assays demonstrated dose-dependent BTK target engagement. Based on pharmacokinetic/pharmacodynamic (PK/PD) simulations, a once-daily dosing regimen (e.g., 100 mg, q.d.) is expected to maintain a high level of BTK inhibition over the dosing interval. Taken together, the safety and PK/PD data support GDC-0853 evaluation in rheumatoid arthritis, lupus, and other autoimmune or inflammatory indications.
20
Activation of BTK by a Phosphorylation Mechanism Initiated by SRC Family Kinases
David J. Rawlings, Andrew M. Scharenberg, Hyunsun Park et al. · Science · 1996 · 459 citations
Akilan Krishnamurthy, Vijay Joshua, Aase Hensvold et al. · Annals of the Rheumatic Diseases · 2015 · 339 citations · Full text
Regulation of Btk Function by a Major Autophosphorylation Site Within the SH3 Domain
Hyunsun Park, Matthew I. Wahl, Daniel Afar et al. · Immunity · 1996 · 329 citations · Full text